secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0000950170-23-030725
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve certificate amendment to extend exculpation to senior officers
--------------------------------------------------------------------------------

- Amendment to restated certificate of incorporation approved to include certain senior corporate officers in director exculpation provision.
- James Cassella and Michael Heffernan elected as Class I directors for terms expiring at 2026 annual meeting.
- Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2023.
- Amendment effective June 28, 2023 upon filing with Delaware Secretary of State.
- Vote results: amendment 37.4M for, 35k against; auditor ratification 44.6M for, 8.7k against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017023030725/0000950170-23-030725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017023030725/trvi-20230628.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-030725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer